Last reviewed · How we verify
Heparin fixed doses
Heparin is an anticoagulant that inhibits blood clotting by potentiating antithrombin III, which inactivates thrombin and other clotting factors.
Heparin is an anticoagulant that inhibits blood clotting by potentiating antithrombin III, which inactivates thrombin and other clotting factors. Used for Thromboembolism prophylaxis in surgical patients, Treatment of acute venous thromboembolism, Prevention of clotting in extracorporeal circulation during anesthesia.
At a glance
| Generic name | Heparin fixed doses |
|---|---|
| Sponsor | SANE-Society of Anesthesiology |
| Drug class | Anticoagulant |
| Target | Antithrombin III (enhancer); Thrombin (Factor IIa) and Factor Xa (indirect inhibition) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Heparin binds to and enhances the activity of antithrombin III, a natural inhibitor of coagulation. This complex rapidly inactivates thrombin (Factor IIa) and Factor Xa, preventing the formation of fibrin clots and the propagation of thrombosis. Fixed-dose heparin formulations provide standardized anticoagulation for prophylaxis and treatment of thromboembolic disorders.
Approved indications
- Thromboembolism prophylaxis in surgical patients
- Treatment of acute venous thromboembolism
- Prevention of clotting in extracorporeal circulation during anesthesia
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Thrombosis
- Osteoporosis (with prolonged use)
Key clinical trials
- The Intensive Care Platform Trial (PHASE4)
- Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin. (PHASE3)
- TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer (PHASE3)
- Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis (PHASE2, PHASE3)
- Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE (PHASE4)
- Optimal Protamine Dosing for Heparin Reversal Following Cardiopulmonary Bypass (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Heparin fixed doses CI brief — competitive landscape report
- Heparin fixed doses updates RSS · CI watch RSS
- SANE-Society of Anesthesiology portfolio CI